Bevacizumab - CISMeF

Preferred Label : Bevacizumab;

MeSH definition : An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF receptors and prevents the proliferation of blood vessels.; An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.; An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.;

MeSH hyponym : avastin; Bevacizumab awwb;

Wikipedia link : https://en.wikipedia.org/wiki/Bevacizumab;

Is substance : O;

UNII : 2S9ZZM9Q9V;

Details

Origin ID

D000068258;

UMLS CUI

C0796392;

ATC code(s)
- bevacizumab [ATC Code]
ATC code(s)
- bevacizumab [ATC Code]
- bevacizumab [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- bevacizumab [ATC Code]
Exact mapping(s) to DCI
- bevacizumab [International Nonproprietary Name]
Pharmacological action(s)
- Antineoplastic Agents, Immunological [MeSH Descriptor]
- angiogenesis inhibitors [MeSH Descriptor]
Record concept(s)
- Bevacizumab-awwb [MeSH concept]
- Mvasi [MeSH concept]
- avastin [MeSH concept]
- bevacizumab [MeSH concept]
Related MeSH Supplementary Concept(s)
- 89Zr-bevacizumab [MeSH Supplementary Concept]
- BEVZ92 [MeSH Supplementary Concept]
- technetium 99m tricarbonyl bevacizumab [MeSH Supplementary Concept]
See also
- receptors, vascular endothelial growth factor [MeSH Descriptor]
See also inter- (CISMeF)
- Product containing bevacizumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Anti-VEGF Monoclonal Antibody [NCIt concept]
- Bevacizumab [NCIt concept]
- Bevacizumab (substance) [SNOMED CT concept]
- Product containing bevacizumab (medicinal product) [SNOMED CT concept]
- bevacizumab [ATC Code]
- bevacizumab [International Nonproprietary Name]
- bevacizumab [ATC Code]
Validated automatic mappings to BTNT
- bevacizumab [ATC Code]
Validated automatic mappings to NTBT
- Anti-VEGF Monoclonal Antibody [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients